Financing Pharmaceutical Innovation: How Much Should Poor Countries Contribute?
William Jack and
World Bank Economic Review, 2005, vol. 19, issue 1, 45-67
A public economics framework is used to consider how pharmaceuticals should be priced when at least some of the research and development incentive comes from sales revenues. Familiar techniques of public finance are used to relax some of the restrictions implied in the standard use of Ramsey pricing. Under the more general model, poor countries should not necessarily cover even their own marginal costs, and the pricing structure is not related to that which would be chosen by a monopolist in a simple way. This framework is then used to examine ongoing debates regarding the international patent system as embodied in the World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights. Copyright 2005, Oxford University Press.
References: Add references at CitEc
Citations: View citations in EconPapers (4) Track citations by RSS feed
There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.
Working Paper: Financing Pharmaceutical Innovation: How Much Should Poor Countries Contribute? (2003)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:oup:wbecrv:v:19:y:2005:i:1:p:45-67
Ordering information: This journal article can be ordered from
Access Statistics for this article
World Bank Economic Review is currently edited by Jaime de Melo
More articles in World Bank Economic Review from World Bank Group Oxford University Press, Great Clarendon Street, Oxford OX2 6DP, UK. Contact information at EDIRC.
Bibliographic data for series maintained by Oxford University Press ().